Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-Label, Multi-Arm, Non-Randomised, Multicentre, Phase 2 Trial
Lancet Oncol 2021 May 11;[EPub Ahead of Print], AG Sacco, R Chen, FP Worden, DJL Wong, D Adkins, P Swiecicki, W Chai-Ho, P Oppelt, D Ghosh, J Bykowski, A Molinolo, E Pittman, MV Estrada, K Gold, G Daniels, SM Lippman, A Natsuhara, K Messer, EEW CohenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.